Efficacy and Safety Study of SHR-1819 Injection in Adult Patients With Severe Atopic Dermatitis

NCT05549947 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

158

Enrollment

INDUSTRY

Sponsor class

Conditions

Moderate to Severe Atopic Dermatitis

Interventions

DRUG: SHR-1819
DRUG: Placebo

Sponsor

Shanghai Hengrui Pharmaceutical Co., Ltd.